Angiotensin-converting enzyme (ACE) inhibitors, introduced in the late 1980s, were a cornerstone, shown to improve hemodynamics, reduce symptoms, and significantly decrease mortality and hospitalizations in patients with heart failure by blocking angiotensin II and aldosterone. [6, 12, 16, 23, 37, 48]